Oxford Biomedica (uk) Limited

Oxford Biomedica, Inc.

James Miskin

Susan Mary Kingsman

Kyriacos Andreou Mitrophanous

Susan Marie Kingsman

Richard Truran

Robert Buckley

Pippa Radcliffe

Jonathan Rohll

Philippa Radcliffe

Fraser J Wilkes

Kyri Mitrophanous

A process for producing a retroviral or lentiviral vector formulation comprising a filter-sterilisation step wherein the filter-sterilisation step is not the final step in the purification process.

Virus purification

Provided is a multicistronic retroviral vector genome having a first nucleic acid sequence upstream of at least one internal regulatory element, such that the level of genomic RNA available for packaging in the absence of rev, or a functional equivalent thereof, is increased.

Viral vector

A process for producing a retroviral or lentiviral vector formulation comprising a filter-sterilization step wherein the filter-sterilization step is not the final step in the purification process.

The present invention provides a vector system comprising a mutated post-transcriptional regulatory element. In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.

Vector system

Growing community of inventors

Oxford, United Kingdom

James Miskin